Abstract Olfactory receptors (ORs) are chemosensors that are responsible for one's sense of smell. In addition to this specialized role in the nose, recent evidence suggests that ORs are also found in a variety of additional tissues including the kidney. As this list of renal ORs continues to expand, it is becoming clear that they play important roles in renal and whole-body physiology, including a novel role in blood pressure regulation. In this review, we highlight important considerations that are crucial when studying ORs and present the current literature on renal ORs and their emerging relevance in maintaining renal function.
Introduction
Olfactory receptors (ORs) are seven transmembrane-domain Gprotein-coupled chemosensors that mediate the sense of smell in the nose. Localized to the cilia on the tips of olfactory sensory neurons (OSNs) ORs exhibit exquisite sensitivity to a diverse range of volatile odorants [1] . Originally identified in 1991 by Linda Buck and Richard Axel, it is now known that there are >1000 OR genes in mice and roughly 350 in humans, making them the largest gene family in the genome [2] [3] [4] . Despite the diversity of molecules that activate these receptors, they all signal through a conserved downstream signaling pathway whereby stimulation by a volatile odorant leads to increased intracellular cyclic adenosine monophosphate (cAMP), which depolarizes the OSN [5] [6] [7] .
In the seminal paper that first described ORs, an assumption was made that OR expression would be restricted to OSNs given their sensory function [1] . While it is true that the expression level of ORs is highest within the olfactory epithelium (OE), it is now clear that at least some ORs are expressed in a variety of additional tissues. With new techniques such as whole transcriptome sequencing, the list of Bectopic ORs^has greatly expanded in the last few years, and these sites now include the gastrointestinal (GI) tract, muscle, heart, pancreas, liver, lung, and skin [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . While the physiological functions that each of these ORs play in nonsensory tissues remain an ongoing area of research, it is evident that ORs serve important roles in physiology. Notably, murine and human ORs have been found in sperm and play a key role in sperm chemotaxis [10, 16] . In addition, mouse OR23 (MOR23) is found in muscle myocytes where it regulates migration and adhesion and contributes to muscle regeneration [11] . The functional importance of these ORs clearly indicates that they likely play novel roles in a variety of different tissues.
Given its sensory functions, the kidney appears to be an ideal organ to take advantage of OR signaling. The epithelial lining of the kidney comes in contact with a diverse range of chemicals, and it must keep careful track of the composition of the tubular fluid as it moves through the different segments of the nephron. The kidney adjusts its filtration, reabsorption, and secretion rates in response to changes in electrolytes and metabolites; thus, it is well suited to take advantage of specialized chemosensors, such as ORs, in order to maintain homeostasis. In this review, we begin by outlining challenges specific to OR biology that shape these investigations and subsequently focus on identifying individual renal ORs and their roles in renal physiology.
Special considerations and challenges of studying ORs
The ectopic expression of sensory receptors such as ORs is an exciting and emerging field. However, several experimental challenges are specific to the study of ORs, and it is imperative that one understands these challenges in order to properly evaluate and understand data regarding OR expression in the kidney and elsewhere. Therefore, here we will briefly review OR-specific best practices.
First, very few antibodies for ORs are available. While Gprotein-coupled receptors in general tend not to be particularly antigenic, ORs are persistently difficult to generate antibodies against (despite enormous efforts in this area). Out of the 1000 murine ORs and 350 human ORs identified thus far, only a few antibodies appear reliable: MOR28 [20] [21] [22] , M50 [23] , M71 [23] , MOR256-17 [24] , MOR11-4 [22] , mOR37A-E [24] , I7 [21] , mOR-EG [21] , MOR10 [25] , MOR18-2 [26] , MOR256-50 [27] , and MOR42-3 [27] . Of these, the only OR expressed in the kidney is MOR18-2, although this antibody strongly cross-reacts with a mitochondrial protein when used outside the OE [26] . It is important to note that although numerous additional OR antibodies are readily available for purchase from multiple vendors and companies, to our knowledge, only two commercially available OR antibodies have been successfully validated (MOR256-50 and MOR42-3 [27] ; note that an antibody for MOR127-1 could not be validated in this same reference). A number of researchers (ourselves and many others) have attempted to validate a great number of additional commercial antibodies, to no avail. Therefore, if one wishes to employ an OR antibody not previously published, proper validation is absolutely critical-typically, at a minimum, demonstration that at least one (preferably both) of the following are true: (a) the antibody gives the expected staining pattern in the OE (if the expression pattern for that particular OR is not known, in situ hybridization coupled with immunohistochemistry would be the appropriate demonstration of specificity), and (b) the antibody recognizes cells transfected with the target protein (as in [26, 27] ). However, even with this validation, it is worth bearing in mind that a positive result would provide key evidence that the antibody recognizes its intended target, but it would not mean that the antibody is specific for the intended target-as opposed to the other~1000 ORs.
In the absence of antibodies, one often turns to other methods, including transgenic mice [i.e., with green fluorescent protein (GFP) or LacZ reporters] and RNA expression. ORs have an Bancient^genomic structure: all mammalian ORs have single-exon coding sequences (although introns can be present in OR genes upstream of the coding exon [28, 29] ). Therefore, when using reverse transcription polymerase chain reaction (RT-PCR), it is important to include mock controls for ORs (where no reverse transcriptase enzyme is added to the RT reaction), as genomic DNA and RNA will yield the same size bands for primers directed against the coding sequence. Likewise, simply because the OR gene family is so large, it is important to sequence RT-PCR products to assure identity; with 1000 murine ORs that all have significant sequence similarity, even the most carefully designed primers may be able to cross-react with a Bsibling^of the intended target. Similarly, in situ hybridization is often employed for OR localization, and once again, one must take care when designing probes that they are specific for the intended OR. When available, knockout (KO) mice can be used to confirm specificity of in situ or antibody signal. When KO mice are not available, the number of glomeruli in the olfactory bulb which expresses the OR is a decent surrogate by which to gauge specificity of an in situ probe or antibody [if the probe is specific for a single OR, one would expect to see signal in two to four glomeruli [30] ; additionally, it is imperative that an in situ evaluating OR expression in glomeruli be isotopic due to the low level of OR messenger RNA (mRNA) expression in axons].
The high sequence similarity within this large gene family presents an additional challenge-identifying orthologs across species. When comparing rat and murine ORs, for example, both gene families have~1000 members, all of which are similar. Identifying an ortholog based on sequence similarity alone becomes quite difficult. Once a putative ortholog is identified based on sequence, in order to prove functional relevance, one ought to demonstrate that the ORs are functional orthologs (i.e., respond to the same ligand).
Indeed, when studying any G-protein-coupled receptor, one typically would consider potential roles for the ligand; however, most ORs are Borphan^receptors, with no known ligand. This is certainly a challenge for researchers in this field. Several well-developed assays can be used to screen ORs for potential ligands-for example, calcium signaling in human embryonic kidney (HEK) cells [31] , cyclic adenosine monophosphate (cAMP)-mediated cystic fibrosis transmembrane conductance regulator (CFTR) activation in oocytes [32] , or cAMP-mediated luciferase activation in HEK cells [33] . However, all these assays absolutely require, as a prerequisite, that the OR be expressed on the plasma membrane. For reasons that remain somewhat unclear, although ORs appear to efficiently traffic to the cell surface in vivo, they typically remain trapped in the endoplasmic reticulum when expressed exogenously in cell lines [34] [35] [36] . This frustrating fact means that screening an OR for potential ligands in a high-throughput, in vitro fashion is not as straightforward as one would hope. Given this, there are several approaches that one could take: First, the clearest solution is to screen ORs that Nature has expressed for us-that is, using native OE to test for potential ligands. Typically, potential ligands are tested while calcium responses are monitored, and if an OSN exhibits a calcium response to a particular ligand, then singlecell RT-PCR will be used to identify the receptor expressed in that OSN [37] (dogma holds that each OSN expresses one, and only one, receptor, in a monoallelic fashion [38] ). Although in many ways this approach is the most straightforward, it is technically demanding, is not high throughput, and-without the use of GFP or another marker-it is difficult to focus research on a particular OR. A second possible approach to screening ORs is to use a variety of aids to help the OR achieve surface expression when exogenously expressed in vitro. A number of studies have identified either chaperones or N-terminal tags that aid in OR surface expression [31, 33, [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] . When successful, this allows for a high-throughput approach focused on a specific OR. Finally, careful and elegant work has found that OR expression exhibits strong developmental regulation in the OE-that is, different ORs may be strategically expressed at different developmental time points [51] . Furthermore, even in an OSN, there is a 4-day lag in the onset of OR expression [52] . Therefore, although it is unknown whether temporal regulation of expression takes place in tissues beyond the OE, it is worth noting that the Babsence^of OR expression does not necessarily mean that the OR is never expressed in that tissue but, rather, that it is not expressed at that time point.
Characterizing OR signaling in the kidney
Despite the challenges of studying ORs, significant progress has been made in characterizing renal ORs. In this section of the review, we begin by discussing the identification of renal ORs and components of their downstream signaling and then explore their relevance to both renal and whole-body physiology.
AC3 and G olf
Despite the fact that there are more than 1000 ORs (in mice), all mammalian ORs-at least in the nose-signal through a conserved downstream signaling pathway. Upon OR-odorant binding, the trimeric olfactory G protein (G olfactory , or G olf ) is activated, triggering stimulation of membrane-bound adenylate cyclase 3 (AC3) (Fig. 1a) [5] [6] [7] . While this signaling pathway is obligatory for olfaction (AC3-null mice cannot smell), the components of this pathway are also expressed outside of the nose [13, [53] [54] [55] , and one of these sites is the kidney. AC3 and G olf are both expressed in the murine kidney at the transcript and protein level [56] , and antibodies have localized them to the distal convoluted tubule and to an extremely specialized structure known as the macula densa (MD). The MD is a group of tightly packed sensory cells localized at the junction between the thick ascending limb and the distal convoluted tubule, where the nephron loops back to the afferent arteriole feeding its own parent glomerulus. MD cells take advantage of this unique placement to monitor tubular fluid composition in the distal nephron and then communicate this information back to the afferent arteriole feeding the parent glomerulus. For example, if MD cells detect a decrease in sodium chloride (NaCl) concentration in the filtrate, they will Btell^the afferent arteriole/glomerulus to increase both glomerular filtration rate (GFR) and renin secretion. Ultimately, both of these actions serve to increase NaCl concentration in the filtrate back toward normal. This fine-tuning of GFR regulation allows for constant and precise regulation at the single nephron level, a process known as tubuloglomerular feedback (TGF).
Consistent with localization to the MD, in AC3 KO mice, both decreased GFR and plasma renin were found. Therefore, as AC3 and G olf both localize to the MD and AC3 KO mice exhibit an altered GFR, it was hypothesized that that the decreased GFR was due to an altered TGF response. However, when TGF was measured using stop-flow pressure with artificial tubular fluid, the response was normal. It should be noted that, to date, individual ORs upstream of G olf and AC3 in the MD have not been identified. As ORs often respond to individual metabolites (see below), it is likely that the absence of an altered TGF response in AC3 KO mice may be because the artificial perfusate was lacking key OR ligands/ metabolites. Nonetheless, it is clear that AC3 and G olf do play important functional roles within the renal nephron.
Olfactory receptors
Given the expression of both AC3 and G olf in the murine kidney, it is reasonable to assume that individual ORs are also found in the kidney. Indeed, using a degenerate primer screening approach that takes advantage of the incredible sequence similarity among ORs, six ORs were initially found to be Fig. 1 Olfactory receptor (OR) signaling pathways. a The canonical OR signaling pathway in the olfactory epithelium. OR ligand binding activates G olfactory (G olf ), leading to increased cyclic adenosine monophosphate (cAMP) via adenylate cyclase 3 (AC3) and subsequent depolarization of olfactory sensory neurons. b Potential OR signaling pathways in the kidney. As G olf and AC3 are not ubiquitous in the nephron, it is likely that an activated renal OR binds a stimulatory G protein (G s ), leading to cAMP production by different adenylate cyclases and changes in renal function. GFR, glomerular filtration rate expressed in whole murine kidney [56] . Further analysis in kidneys from multiple independent mice determined that four of these original six ORs are consistently expressed in every sample examined. As such, this initial screen revealed four novel renal ORs (Olfr78, Olfr90, Olfr1392, and Olfr1393). As degenerate primer screens are likely to pick out only the most highly expressed ORs, more recent targeted RT-PCR screens have also been performed to identify additional renal ORs [57] . Using this strategy, an additional six ORs were identified in whole kidney (Olfr99, Olfr545, Olfr691, Olfr693, Olfr31, and Olfr1426). All ten of these murine renal ORs have been cloned from the kidney from start to stop, confirming full-length expression of the coding mRNA (Table 1 ). In addition to targeted screens, renal ORs have also been identified in mice by microarray studies. Notably, several ORs are expressed by microarray analysis in isolated juxtaglomerular cells or in renin-containing cells, and their expression may be developmentally regulated (Table 1 ) [59] . It will be important to confirm these microarray data by sequencing and to examine their potential developmental regulation in more detail. Also, a number of intriguing RNA sequencing screens have found renal OR expression in different segments of the nephron. While this data is as yet unpublished, raw data sets are readily available in the GenitoUrinary Development Molecular Anatomy Project (GUDMAP.org).
Renal OR expression is not unique to the mouse-indeed, ORs are also known to be expressed in rats and humans (Table 1) . A recent RNA sequencing study on human tissues found that ORs are broadly expressed in different tissues, and at least 13 different ORs are expressed in human kidney (excluding pseudogenes) [61] . Similar findings have emerged in the rat. Using hand-dissected nephron segments and isolated glomeruli, the Knepper lab localized five different ORs within the rat nephron [60] . It is important to keep in mind that identifying functional orthologs based on sequence identity alone is usually not possible. Thus, it will be crucial to determine localization and ligand profiles of this expanding list of renal ORs in order to determine their common functions. To date, a handful of ORs have been characterized, and we explore what is known about them in the next few sections.
OR localization
The renal nephron is composed of a number of specialized cell types, all with important and unique functions. Therefore, it is important to know where these renal ORs are expressed in order to understand potential physiological functions. As noted above, antibodies for these receptors are consistently unreliable, and very few exist for renal ORs. Therefore, alternative methods are often used to determine OR localization. Using hand-dissected nephron segments and isolated glomeruli, all five rat renal ORs thus far identified are localized within the kidney [60] . One of these, OR1104, is highly expressed in a single nephron segment-the distal convoluted tubule-while others are found more widely distributed along the length of the nephron (Table 1) . Two ORs are exclusively expressed in rat glomeruli, although individual cell types are not yet known. In addition, mouse renal Olfr90 is expressed in an MD cell line [56] .
While not yet confirmed in vivo, this data suggests that Olfr90 may be one OR that signals via AC3 and G olf and may participate in AC3-mediated renin release/GFR response. Finally, using a LacZ reporter from a KO mouse, it was established that Olfr78 localizes to the renal afferent arteriole and large renal vessels (i.e., renal artery); the physiological function of this OR is expanded on in detail below.
While the majority of renal ORs have not yet been localized, it is likely (based on both published and unpublished data) that they are widely distributed throughout the nephron. However, AC3 and G olf display a much more restricted localization pattern, as they are both found primarily in the distal tubule and MD [56] . While AC3 and G olf are thought to be the obligate downstream signaling molecules in OSNs, this does not appear to be the case in the kidney. Since ORs have been found in cell types that lack AC3 and G olf (i.e., Olfr78 in the afferent arteriole [58] ), these receptors clearly must signal through a different G protein. Consistent with this, ORs in vitro can also couple to G s (or, under specific conditions, G q ) [31, 32, 39, 57, 58, 67] . In addition, a handful of ORs are expressed in the vomeronasal organ, the site of pheromone sensing in the mouse, where they are also thought to couple to other G proteins [68, 69] . Additionally, it is also possible that renal ORs signal through AC3 but not G olf or vice versa. This is supported by the fact that AC3 can be stimulated by other G s proteins [6, 55] . Clearly, additional studies are required to determine the complete expression pattern of ORs within in the kidney and to delineate their downstream signaling (Fig. 1b) .
OR ligands
Most ORs are orphan receptors with no known ligands, and the subset of renal ORs are no exception (Table 1) . Deorphanizing these receptors is a critical step in determining the function of these renal ORs, and to date, some of these renal receptors have known ligands. As mentioned above, functional heterologous expression must be achieved before ligand screening can occur in vitro. With the help of various tags and chaperone proteins, nine different renal murine ORs have been found to traffic to the cell surface in HEK293T cells [39, 57] . Ligand screens have been performed on these ORs, leading to identification of several different OR-ligand pairs. Olfr78 and its human ortholog hOR51E2 both respond to short-chain fatty acids (SCFAs) and the functional relevance of this is discussed in detail below. Olfr691 responds to a wide range of short-and medium-chain fatty acids RT-PCR reverse transcription polymerase chain reaction, RNA-seq RNA sequencing, JG cells juxtaglomerular cells, DCT distal convoluted tubule, S3 third segment of proximal tubule, LDLIM long descending limb of the loop of Henle in the inner medulla, tAL thin ascending limb of the loop of Henle, IMCD inner medullary collecting duct a Sebacic acid was initially reported as a ligand [63] but was not confirmed in a recent screen [57] [ 47, 57] (Table 1) . Notably, one of these ligands, valproate, has been used as an antiepileptic drug, and patients treated with valproate have been shown to develop Fanconi syndrome [70, 71] . This link could potentially reveal a novel mechanism by which proximal tubule transport is regulated, and it highlights the clear importance of understanding the ligands and functional roles for ORs in the kidney.
Olfactory receptor 78: a novel mechanism of blood pressure regulation
Olfr78 (MOR18-2) was initially identified in 2009 as being expressed in whole kidney [56] . Although an antibody against Olfr78 was successfully generated [26] , it strongly crossreacts with a mitochondrial protein in all tissues outside of the olfactory epithelium, including the kidney. Therefore, a transgenic mouse model in which LacZ expression is driven by the Olfr78 promoter was used to identify cell types that normally express Olfr78. Using this tool, Olfr78 was found in the renal afferent arteriole [58] of the renal juxtaglomerular apparatus (JGA). Interestingly, the rat ortholog for Olfr78 (Olr59) has been found in whole glomeruli (Table 1 ) [60] , suggesting that this localization pattern is conserved across species. In addition, LacZ staining of nonrenal tissues revealed that Olfr78 also localizes to small resistance vessels in a variety of vascular beds in the peripheral vasculature (Fig. 2) . It is intriguing to note that both the JGA and the peripheral vasculature are classic sites known to play key roles in blood pressure regulation and that the human ortholog of Olfr78 (hOR51E2) is also expressed at the RNA level in tissues, consistent with these findings [61] (kidney, skeletal muscle, heart, etc.). Although Olfr78 was initially an orphan receptor, an in vitro ligand screen revealed that it is a receptor for SCFAs-specifically, acetate and propionate [58] -and that the human ortholog of this receptor (hOR51E2) responds to the same two compounds. Although identifying OR orthologs across species is typically problematic, this OR appears to be uniquely well conserved among mammalian species (with a clear ortholog in mice, rats, rabbits, elephants, horses, and five species of primates [72] ). As G olf is not expressed in the afferent arteriole [56] , Olfr78 in the afferent arteriole likely couples to G s .
Intriguingly, SCFAs are present in the bloodstream primarily due to production by gut microbiota [73] ; bacteria in the gut produce SCFAs in large quantities (such that the concentration in the colonic lumen is~100 mM [73] ) and are then absorbed into the bloodstream in the low millimolar range (0.1-10 mM [74] [75] [76] [77] ). The half maximal effective concentration (EC 50 ) of Olfr78 for acetate (2.35 mM) and propionate (0.92 mM) falls within this plasma range. SCFAs produced by gut microbiota play important roles in influencing several aspects of host physiology, including inflammatory responses and metabolism [75, 78] .
As mentioned, Olfr78 localizes to two important sites of blood pressure control. One of these sites is the afferent arteriole. Here, renin-the rate-limiting step in the reninangiotensin-aldosterone pathway-is stored and secreted into the bloodstream. Renin is responsible for hydrolysis of angiotensinogen to angiotensin I, which is further cleaved to angiotensin II, a potent vasoconstrictor (Fig. 2) . Because Olfr78 localizes to the renal afferent arteriole, it was investigated whether Olfr78 might mediate an increase in renin secretion in response to SCFAs. Indeed, in an ex vivo preparation, SCFAs induced renin release, and that effect was dependent on Olfr78 [58] . Furthermore, in support of this, Olfr78 null animals had lowered plasma renin and lowered baseline blood pressure [58] (Fig. 2) . Thus, these findings present a novel pathway whereby activation of the sensory receptor Olfr78 mediates changes in plasma renin and in blood pressure. It should be noted that some ORs are mechanosensitive [79, 80] ; however, it is unknown whether Olfr78 may be responding to mechanical (changes in blood flow?) as well as chemical stimuli.
Because Olfr78 also localizes to the peripheral vasculature, it was also determined whether SCFAs might also have an acute effect on vascular resistance, another important aspect of blood pressure control. Previous studies reported that SCFAs can indeed induce vasodilation in isolated vessels [81] [82] [83] , and to determine whether there was an in vivo consequence of this vasodilation, SCFAs were delivered exogenously (intravenously) and blood pressure measured. It was found that SCFA delivery caused a rapid, reproducible, and Fig. 2 Short-chain fatty acids (SCFAs) produced by gut microbiota activate Olfr78 in the renal juxtaglomerular apparatus (JGA) and peripheral vasculature. Activation of Olfr78 in the JGA leads to increased renin release. In the peripheral vasculature, activation of Olfr78 modulates a hypotensive response mediated by other SCFA receptors. In both cases, activation of Olfr78 leads to an increased blood pressure response dose-dependent hypotensive response. However, subsequent studies showed that this response is primarily due to activation of another SCFA receptor (Gpr41), whereas Olfr78 acts as a Bbrake^on this response. Therefore, Olfr78 activation by SCFAs serves to increase blood pressure through two independent methods: (i) increased renin release from the JGA, and (ii) changes in peripheral vascular resistance (Fig. 2) . (The opposing actions of Olfr78 and Gpr41 on blood pressure regulation have been reviewed in detail [84, 85] .)
Conclusion
In conclusion, recent studies have highlighted novel and unexpected roles played by ORs in a variety of tissues. As a key regulator of homeostasis, the kidney is a particularly intriguing location for such receptors, and studies have shown that ORs are found in the kidney. Although there are a number of challenges to studying ORs, it is important that future studies carefully explore and elucidate the novel roles that these receptors play in renal function.
